SCHEMBL6470819

SCHEMBL6470819

CCCCN(CCCC)c1cncc(N)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 1/20 0.35
LMNA P02545 1/20 0.35
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPT P10636 4/20 0.33
NPSR1 Q6W5P4 2/20 0.32
KDM4E B2RXH2 2/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
NOS2 P35228 1/20 0.32
ELANE P08246 1/20 0.31
GBA1 P04062 1/20 0.31
GABRP O00591 1/20 0.31
GABRD O14764 1/20 0.31
GABRA1 P14867 1/20 0.31
GABRB1 P18505 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6468487 0.84 HRH3 (0.37) CDK2MEN1KMT2AMAPTKDM4E
SCHEMBL13101036 0.81 KDM4E (0.43) CDK2KMT2AMAPTKDM4EMAPK1
SCHEMBL3186724 0.79 HRH3 (0.36) CDK2KDM4EALDH1A1
SCHEMBL6470817 0.76 CNR1 (0.35) LMNAMEN1KMT2AKDM4ECNR1
SCHEMBL29082814 0.70 POLB (0.49) LMNAMAPTNPSR1KDM4EMAPK1
SCHEMBL10375671 0.70 LMNA (0.43) LMNAMEN1KMT2AMAPTNPSR1
SCHEMBL13447375 0.68 NOS2 (0.55) CDK2NOS2GABRPGABRDGABRA1
SCHEMBL6469127 0.67 TLR8 (0.53) CDK2LMNAMAPK1HTTALDH1A1
SCHEMBL6469274 0.67 MAPT (0.36) LMNAMEN1KMT2AMAPTNPSR1
SCHEMBL3193118 0.66 TLR8 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US claimed
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA CDK2 1835/4885LMNA 1292/4885MEN1 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.